Duncan Peyton
Founder chez 4D PHARMA PLC
Profil
Duncan Peyton is the founder of Aquarius Equity Partners Ltd.
(founded in 2005) and 4D Pharma Plc (founded in 2014), where he holds the titles of Director and CEO, Secretary & Executive Director, respectively.
He also held former positions as an Independent Non-Executive Director at hVIVO Ltd.
(2012-2014), Director at GT Biologics Ltd., Non-Executive Director at C4X Discovery Ltd., and Investment Manager at 3i Plc.
Additionally, he worked at Addleshaw Booth & Co. from 2004 to 2007.
Mr. Peyton received an undergraduate degree from the University of Sunderland.
Postes actifs de Duncan Peyton
| Sociétés | Poste | Début |
|---|---|---|
| 4D PHARMA PLC | Founder | 18/01/2014 |
Aquarius Equity Partners Ltd.
 Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Founder | 01/01/2005 |
Anciens postes connus de Duncan Peyton
| Sociétés | Poste | Fin |
|---|---|---|
| HVIVO PLC | Director/Board Member | 21/05/2014 |
3i Plc
 3i Plc Financial ConglomeratesFinance 3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom. | Chief Investment Officer | - |
GT Biologics Ltd.
 GT Biologics Ltd. Pharmaceuticals: MajorHealth Technology GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom. | Director/Board Member | - |
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | - |
Formation de Duncan Peyton
| University of Sunderland | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 4D PHARMA PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
hVIVO Ltd.
 hVIVO Ltd. Miscellaneous Commercial ServicesCommercial Services hVIVO Ltd. engages in the provision of clinical development services with a focus on human disease models. It specializes in human challenge studies using influenza, human rhinovirus, and respiratory syncytial virus for pharmaceutical and biotech companies. The company was founded by John Sidney Oxford in 1989 and is headquartered in London, the United Kingdom. | Commercial Services |
3i Plc
3i Plc Financial ConglomeratesFinance 3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom. | Finance |
Aquarius Equity Partners Ltd.
Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Finance |
GT Biologics Ltd.
GT Biologics Ltd. Pharmaceuticals: MajorHealth Technology GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom. | Health Technology |
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |
